Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
29.11
-2.43 (-7.70%)
At close: Apr 28, 2026, 4:00 PM EDT
28.53
-0.58 (-1.99%)
After-hours: Apr 28, 2026, 7:08 PM EDT
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
39.02M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Plus Therapeutics | 5.21M |
| Aligos Therapeutics | 2.19M |
| Werewolf Therapeutics | 1.14M |
| Rallybio | 858.00K |
| Mereo BioPharma Group | 500.00K |
| Actinium Pharmaceuticals | 90.00K |
SNSE News
- 12 days ago - Sensei Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 19 days ago - Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 4 weeks ago - Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 6 weeks ago - Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Sensei Biotherapeutics Transcript: M&A announcement - Transcripts
- 2 months ago - Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire
- 3 months ago - Egle Therapeutics Appoints John Celebi as Chief Executive Officer - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire